NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 16 February 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Peter Jackson (Chair) Present for all items
2. Dr Paul Arundel (Vice Chair) Present for all items
3. Professor Philip Beales Present for all items
4. Sarah Davis Present for all items
5. Stuart Davies Present for all items
6. Carrie Gardner Present for all items
7. Dr Shehla Mohammed Present for all items
8. Francis Pang Present for all items
9. Karen Samuels Present for all items
10. Dr Mark Sheehan Present for all items
11. Matt Smith Present for all items
12. Professor Lesley Stewart Present for all items
13. Karen Whitehead M.B.E Present for all items

NICE staff present

Richard Diaz, Associate Director Present for all items

Gavin Kenny, Project Manager Present for all items

Emily Eaton Turner, Technical Analyst Present for items 4.1.3 to 5

Neha Jiandani, Technical Analyst Present for all items

Jo Richardson, HTA Analyst Present for all items

Steve Norton, HTA Analyst Present for all items

Samantha Bakersville, HTA Analyst Present for items 4.1.3 to 5

Nigel Gumbleton, HTA Analyst Present for all items

Heidi Livingstone, Senior Advisor, PiP Present for items 1 to 4.1.3

Ella Fitzpatrick, Coordinator, PiP Present for items 1 to 4.1.3

Hayley Garnett, Senior Medical Editor Present for all items

Lyn Davies, Coordinator, MiP Present for items 1 to 4.1.3

Emma Gordon, Administrator, TA Present for all items

Laura Kelly, Administrator, COT Present for all items

**External assessment group representatives present**

Robert Wolff, EAG Representative, KSR Present for items 1 to 4.1.3

Sue O’Meara, EAG Representative, KSR Present for item 4.1.3

Isaac Corro Ramos, EAG Representative, KSR Present for items 1 to 4.1.3

Experts present

Vanessa Martin, Chair, Childhood Tumour Trust. Present for items 1 to 4.1.3

Dr Karine Lascelles, Consultant Paediatric Neurologist, Present for items 1 to 4.1.3 British Paediatric Neurology Association

Ayesha Ali, NHS Commissioning representative. Present for items 1 to 4.1.3

Clare Barklam, Educational Advocate,  Present for items 1 to 4.1.3 Childhood Tumour Trust

Observers present

Karen Facey, Researcher, NICE Present for all items

Victoria Charlton, Researcher Present for all items

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. Apologies from Professor Ron Akehurst, Sotiris Antoniou and Jeremy Manuel were received prior to the meeting.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 13 January 2022

### Evaluation of Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from AstraZeneca Ltd.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Dr Karine Lascelles declared a direct financial interest Due to participating in NF1 consultancy meetings/ masterclass as an external expert for AstraZeneca (date of meeting 2nd July 2021) and was remunerated for their time. It was agreed that his declaration would not prevent Dr Lascelles from participating in this section of the meeting.

Vanessa Martin has declared an indirect financial interest, as the Childhood Tumour Trust has received an educational grant from AstraZeneca and Vanessa has worked with them by attending a patient advocacy group advisory board. It was agreed that his declaration would not prevent Vanessa Martin from participating in this section of the meeting.

Clare Barklam has declared a direct financial interest, as they attended a committee/working group hosted by AstraZeneca for a patient charter for Neurofibromas and a nominal fee was paid for their time. Clare has also declared an indirect financial interest as their organisation has received an educational funding grant from AstraZeneca. It was agreed that his declaration would not prevent Clare Barklam from participating in this section of the meeting.

* + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by The Chair, Dr Peter Jackson.
	1. Part 2 – [Closed session] (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Evaluation Consultation Document (ECD) or Final Evaluation Determination (FED). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-hst10045>.

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Wednesday 13 April 2022 and will start promptly at 09:30am.